Introduction
Coxsackievirus B3 (CVB3) is considered as the most important infectious agent that can cause severe heart complications. CVB3 is associated with both acute and chronic forms of myocarditis (inflammation of the myocardium), a life threatening disease (Reyes and Lerner, 1985; Woodruff, 1980) . Chronic forms of this disease may lead to dilated cardiomyopathy (DCM), for which the only available and effective treatment is the highly cost heart transplantation procedure. Entroviruses, in general, and CVB3, in particular, are responsible for causing up to 30-45% of acute forms of myocarditis and 25% of DCM (Bowles et al., 1986; Frisk et al., 1984) . In an infected cardiomyocyte, cleavage of dystrophin by viral 2A pro is considered an important mechanism for CVB3-induced cardiac injury (Badorrf et al., 1999) . CVB3 infection is also associated with programmed cell death and apoptosis in myocardial tissue (Goldstaub et al., 2000; Olivetti et al., 1997) . CVB3 is a picornavirus, a family of small positive-stranded RNA viruses associated with a large variety of human and animal diseases. Following virus entry, viral RNAs are translated, and newly synthesized viral proteins are released within the cytoplasm of infected host as large a polyprotein, which will be then processed and further cleaved by virus-specific protease 2A and 3C to generate mature structural and nonstructural viral proteins (Krausslich and Wimmer, 1988; Skern and Liebig, 1994) . Viral replication depends on this proteolytic cleavage. Although the newly synthesized viral polyprotein is processed mainly by 3C pro , the primary cleavage event separating the structural protein precursor from the nonstructural one is performed by 2A pro (Hanecak et al., 1982; Toyoda et al., 1986) .
Viral protease 2A is a multifunctional chymotrypsin-like cysteine proteinase that catalyzes the cleavage of the viral polyprotien at a tyrosine-glycine pair between the C-terminus of VP1 and its own Nterminus (Rueckert, 1996; Toyoda et al., 1986) . Both 2A pro and 3C pro are also responsible for the cleavage of the other cellular proteins such as the eukaryotic Initiation Factor-4G (eIF4G) and the cytoplasmic protein dystrophin. Cleave of eIF4G (formerly known as p220) leads Contents lists available at ScienceDirect Virology j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y v i r o to the shut-off of the host cell protein synthesis machinery (Hellen et al., 1991; Seipelt et al., 2000; Ventoso et al., 1998) . Another protein of the cellular translation apparatus, poly-ADP-ribose-polymerase (PARP), is also cleaved by 2A pro and 3C pro (Calandria et al., 2004) .
Due to the unique protein structure and essential role played by 2A pro and 3C pro in viral replication and disease progression, they have been considered as potential therapeutic targets to block virus replication and virus-induced cell injury (Krausslich and Wimmer, 1988; Sablina and Antonov, 1991) . Despite considerable efforts in recent years, no promising antiviral compound for CVB3-induced heart diseases has been developed. In the present study the cleavage motif of CVB3 2A pro substrate was used to generate a potent competitor peptide that potentially competes with and blocks 2A pro activity and subsequent viral replication. In order to further study the effect of the newly designed peptide on 2A pro activity, we used a tetracycline-dependent (Tet-on)
expression HeLa cell line, in which the expression of viral 2A pro was conditionally controlled. Such tightly controlled system provided us with the proper tool to monitor the direct interaction between conditionally overexpressed viral 2A protease and the synthesized competitive peptide in a timely manner.
Results
In vitro activity of the purified 2A
pro
To ensure the integrity of the purified 2A pro and the efficiency of the cloning and transformation, 2A pro gene was approved by sequencing in pET22b. After purification, to assay the activity of the 2A pro , the cleavage of eIF4G, as the specific substrate of 2A pro and a component of eIF4F, was analyzed. As shown in Fig. 1 , addition of the purified enzyme resulted in complete cleavage of eIF4G, indicating that the purified 2A pro was active.
Isolation of HeLa cell clones expressing coxsackievirus B3 2A pro under the control of Tet-on expression system
The Tet-On inducible gene expression system provides ready access to a tightly regulated, high-level gene expression system as described by (Gossen et al., 1994) with modifications made by (Urlinger et al., 2000) . In the Tet-On system, expression is activated by the addition of doxycycline (Dox), a tetracycline derivative, to the culture medium. This permits gene expression to be tightly regulated a specific stimulus (e.g., doxycycline). Unlike other inducible mammalian expression system, gene regulation in the Tet-on/off systems is highly specific, so results are not complicated by pleiotropic effects or nonspecific inductions.
A stable double-transformed HeLa Tet-On/2A pro cell was established as described in the Material and methods section. After selection and cell cloning, hygromycin resistant cell clones were screened for expression of 2A pro by RT-PCR. Two clones, 4 and 5, were clearly positive in this method (Fig. 2) . Dox was added to 80% confluent double-stable cells as well as noninducible HeLa cells ( Fig. 3a) and 1 day after addition of Dox to selected clones, cells round up (Fig. 3b , Tet-on HeLa cells), and after 48 hours of incubation less than 1% of cells remained viable and attached to the culture plate (Fig. 3c , Tet-on HeLa cells). In the presence of doxycycline, these clones displayed a high expression of viral 2A pro , PARP protein cleavage, and an increased level of apoptosis.
Homology modeling and structure prediction
Multiple sequence alignment of CVB3 and HRV2 2A pro revealed that conserved residues are spread along the whole sequence but Nterminal regions are the least conserved residues (Maghsoudi et al., 2008) . Judging from such a high sequence homology, a high-quality 3D structure of CVB3 2A pro can be expected in homology modeling. It is indeed well known that a homology-modeled structure of a target protein can be accurate enough to be used in a docking study once the sequence identity between target and template approaches 40% (Baker and Sali, 2001 ).
Topology of predicted homology model of CVB3 2A pro
To determine the 3D structure of the protein, an ensemble of 25 model structures was generated. Table 1 presents a comparison between the accessible surface area (ASA) obtained using HM-and PHD-derived results. The overall ASA HM structure and PHD derived ASA are similar. Therefore, the HM-predicted structure is confirmed by PHD data. The overall tertiary structure of CVB3 2A pro strongly resembles that of its template HRV2 2A pro . Fig. 4a shows the schematic representation of a homology model of CVB3 2A pro showing arrangement of structural elements. The tertiary structure comprises beta barrel globally. This domain type is common among proteases and it resembles trypsin-like protease. Reactions stopped by addition of sample buffer and were subjected to 7.5% SDS-PAGE and Western blot using anti-17CV antibody. Negative control for S10, and molecular weight marker have been shown in lanes 1 and 5, respectively. 
Inhibition of CVB3 2A pro by peptide
In order to understand the specificity of CVB3 2A pro , an oligopeptide structurally determined by molecular dynamics was docked into the substrate binding site. The cleavage site for both HRV2 and CVB4 2A pro corresponding to GRTTLSTR↓GPPRGGPG in human eIF4G (Lampheaer et al., 1993) . We studied to determine whether CVB3 2A pro has the same cleavage site since HRV2 and CVB3 2A pro have a strong similarity in their active sites. In addition, Wang et al. (1998) reported that HRV2 2A pro cleaves a peptide corresponding to its own cleavage site in vitro.
To design inhibitors with great potency against enzymes, substrate sequence was used. The nomenclature Pn-P1-P1′-Pn′, of substrate or inhibitor was reported by Lampheaer et al. (1993) with the scissile peptide bond lying between P1 (Arg) and P1′ (Gly). As shown in Fig. 4b , among different binding possibilities, this peptide has high affinity for two amino acids located in the enzyme active site (binding energy of −402.6 kJ/mol). Such affinity cannot be found at the other sites. Replacing Arg in P1 with Asp resulted in a significant decrease in affinity for enzyme (data not shown).
Electrostatic complementarities of interacting surfaces are important factors for protein-protein interaction. In our previous investigation, we showed that CVB3 2A pro is a negatively charged protein (Maghsoudi et al., 2008) , which makes it more possible for a substrate with positive potential to enter the active site. In Fig. 4c , the global electrostatic potentials of the residues have been mapped on the protein surface, which has been found to be a negatively charged protrusion, symbolized as a red bump. These calculations indicate that the best ligand-receptor complementary electric field appears in one ligand binding site, which was confirmed by HEX output as the most stable one as well. In a separate investigation, the inhibitory effect of this peptide on 2A pro -substrate (eIF4G) was determined experimentally by an in vitro cleavage assay. As shown in Fig. 4d , this peptide could significantly decrease eIF4G cleavage by viral 2A pro .
In addition, Western blot analysis has shown that the proteases 2A can cleavage the poly-ADP-ribose-polymerase (PARP). The cleavage is partially blocked by 50 μg/ml of designed peptide, suggesting an inhibitory effect of the synthesized peptide on viral 2A pro activity (Fig. 5) . Results from the cell viability assay (MTT) have also shown that at the concentration of 100 μg/ml, our synthesized peptide can completely blocks 2A pro activity and subsequent cell death whereas the scrambled peptide (Arg in P1 was replaced by Asp in its sequence) could not inhibit cell death significantly (Fig. 6 ). The docking of 2A pro -substrate along with our experimental data would thus support a direct cleavage of eIF4G that continues to be the subject of much debate (Bovee et al., 1998) .
Discussion
Coxsackievirus B3 (CVB3) is the most common cause of inflammatory heart diseases and the subsequent end-stage cardiomyopathy (Gillum, 1986; Reyes and Lerner, 1985; Sugrue et al., 1992; Woodruff, 1980) . CVB3 genome encodes two proteases, 2A and 3C, which are responsible for processing the viral polyprotein, and therefore, for production of all mature viral particles (Krausslich and Wimmer, 1988; Skern and Liebig, 1994) . In addition, they are involved in the cleavage of host cells proteins essential for normal cellular homeostasis and functions such as transcription, translation and cytoskeletal integrity (Badorrf et al., 1999; Hellen et al., 1991; Seipelt et al., 2000; Ventoso et al., 1998) . Due to their unique protein structures and essential roles in viral replication, 2A and 3C proteases have been considered as suitable targets for blocking virus replication and its destructive effect within the host cell (Krausslich and Wimmer, 1988; Sablina and Antonov, 1991) . Considering their crucial roles during virus life cycle, inhibition of these proteases may be an excellent strategy to restrain viral replication and resulting detrimental effects on the heart and other infected organs. (Schotte et al., 1999) . During the last decade, the need for an antiviral drug with no side effect on host cells normal physiological functions has been increasing. The main challenge is to design an effective and highly specific inhibitor capable of blocking viral replication, preferably during the early phase of virus life cycle. A rational strategy to develop a specific protease inhibitor should be based on the structure and function of the protease. Unfortunately, no report of the threedimensional structure of CVB3 2A pro has been published. We therefore predicted the 3D structure of CVB3 2A pro based on the comparative homology modeling. In the absence of a crystal structure, our study can provide a rational alternative for structure-based drug design. So, in the present study, we have focused on designing a highly specific competitor peptide in an attempt to block the activity of CVB3 2A pro in a HeLa cell culture model. To analyze the effect of the synthesized peptide on 2A pro , we used a tetracycline (Tet)-dependent expression system. This system can constitute an easy and rapid screening method for identification of Our results have shown that 2A pro activity is inhibited more than 60% by 50 μg/ml peptide; therefore, the peptide is likely to be structurally very similar to 2A pro substrate and can be effective and specific tool for inhibiting of 2A pro action, preventing the apoptotic effect on host cells, and suggesting an effective and feasible therapeutic approach for viral myocarditis.
There are other approaches to control CVB3 replication, amongst which are reports on application of siRNA to block its replication (Yuan et al., 2005; Merl et al., 2005) . However, the main challenge for siRNA is still the problem with the targeted delivery and nonspecific bindings (Zhang et al., 2009 ). Another limitation is that siRNA targeting CVB3 mRNA strand is probably more effective during the very early stages of virus replication and is more practical when virus infection is detected early. The efficiency of such approach during the chronic phase of infection, in which most of the cytotoxic effects caused by virus in due to the cleavage of host cell proteins by viral proteases, is a matter of question. Such limitation in siRNA delivery warrants further investigation to establish inhibitory peptides that are more specific in binding to the protein of interest, and easier to deliver.
In conclusion, this study is a proof of principle that demonstrates a well-established, tightly controlled and consistent in vitro model for studying and monitoring the inhibition of viral protease 2A functions and destructive effects. Furthermore, the observation that our 16-mer peptide appears to be highly modifiable will provide us with possibilities in the future to improve its structure to achieve a higher-affinity or a potent noncompetitive and specific inhibitor for protease 2A. The ultimate goal is to test the inhibitory peptide in an in vivo animal model of viral myocarditis.
Materials and methods

Viral RNA preparation
Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) was used for growth and maintenance of HeLa cells cultures. Subconfluent cell cultures were infected with 10 5 plaque-forming units (PFU) CVB3 in a medium containing 1% fetal bovine serum. Cell lysates were then collected at 24 hrs post-infection Positive clones of HeLa cells grown in flasks were treated by Dox (300 ng/ml) to express 2A pro , and were then treated with 50 μg/ml of peptide. PARP cleavage was measured by
Western blot analysis using anti-PARP monoclonal antibody. by centrifugation at 300 × g for 10 min and total RNA was extracted by RNX solution as described by the manufacturer (Cinagen, Iran). Briefly, after homogenizing the cells, 1 ml of RNX solution was added to the tube and incubated at room temperature for 5 min. Chloroform was added to the solution and centrifuged for 15 min at 12,000 RPM. The upper phase was then transferred to another tube and an equal volume of isopropanol was added. The mixture was centrifuged for 15 min at 12,000 RPM and the resulting pellet was then washed in 70% ethanol and dissolved in DEPC-treated water.
Construction of expression vector
cDNA that was generated from PCR product of 2A pro was cloned into pET22b vector, and the direction of cloning was confirmed. For expression, pET-2A pro recombinant vector was transferred to Escherichia coli BLR(DE3)pLysS strain and IPTG was used to express 2A pro as described previously (Maghsoudi et al., 2008) . Finally, purification was performed by Q-Sepharose column (Pharmacia, Sweden). The ability of purified 2A pro to cleave eIF4G, a natural substrate of 2A pro , was assayed on postmitochondrial HeLa cell extracts (S10) that were obtained as described by Brown and Ehrenfeld (1979) . The S10 extract was incubated with 5 μg of purified 2A pro protein for 2 hours at 37°C. The reaction was stopped by adding 1/4 volume of 4× sample buffer (640 mM Tris-HCl pH 6.8, 8% SDS, 20% 2-mercaptoethanol, 40% glycerol, 4 mM PMSF, and 0.015% bromophenol blue). The samples were analyzed by Western blotting using a polyclonal antibody against eIF4G. Production of rabbit antiserum against eIF4G was carried out as previously described (Maghsoudi et al., 2008) .
Generation of stably transformed HeLa cells bearing the CVB3 2A pro gene
The Tet-On system is based on two mutant "reverse" Tet repressors (rTetRs) that bind to tetO in the presence of doxycycline (Sigma, USA). These rTetRs have been fused to VP16 AD. The resulting trans-activators (rtTA) activate transcription from a TRE as a consequence of doxycycline treatment (Gossen et al., 1994; Hillen and Berens, 1994; Urlinger et al., 2000) . To establish a stably transformed HeLa cell line, 2A
pro gene was subcloned in pBI-G Tet vector (Clontech, USA). The pBI-G Tet Vector contains the bidirectional promoter Pbi-1, which is responsive to the tTA and rtTA regulatory proteins in the Tet-Off and Tet-On systems, respectively.
Construction of pBI-G-2A pro
The pET22b plasmid containing 2A pro gene was used as the template and PCR was performed. One pair of primers was used for this part of preparation: F-2ak containing the PstI restriction site (underlined) and Kozak sequence (5′-ATCCTGCAGACCACCATGGGCG-CATTTGGACAAC-3′), and R-2a containing SalI restriction site (underlined) (5′-ACGGTCGACTCACTGTTCCATTGCATCATC-3′). PCR was carried out by PFU polymerase under the following conditions: initial denaturation at 94°C for 5 min, 35 cycles (94°C for 1 min, 68°C for 1 min, and 72°C for 1 min), and a final extension for 5 min at 72°C. The PCR products digested by PstI/SalI were inserted into the PstI/SalI restriction sites of digested/dephosphorylated pBI-G vector (Clontech, USA) and ligated mixtures were transformed into competent cells of E. coli DH5α using the electroporation method.
Preparation of a stable Tet-On HeLa cell line
Increasing concentrations (0, 50, 100, 200, 400 , and 800 μg/ml) of Geneticin (G418) (MP Biomedicals, USA) were tested on HeLa cell cultures to find a suitable concentration for developing the stable cell line. HeLa cells were transfected with 5 μg of pWHE134 containing neoR using the electroporation technique. Successfully transfected colonies were selected based on their response to G418, which resulted in massive cell death in ∼5 days. Two to four weeks following treatment, G418-resistant HeLa cell colonies appeared. Large, healthy colonies were selected and transferred to individual plates. HeLa TetOn Cells were grown and maintained in DMEM supplemented with 10% FBS and 150 μg/ml of G418 (GIBCO BRL, USA).
Development of a double-stable Tet-On HeLa cell line
A 60-mm-diameter plate seeded with 10 6 HeLa Tet-On cells was cotransfected with 5 ng of pBI-G-2A pro encoding the CVB3 2A pro under the control of the tet-responsive promoter, and 250 ng of linear hygromycin marker (Clontech, USA). The transfection was carried out by electroporation. Double-transfected HeLa cells were selected in the presence of 200 μg/ml hygromycin B (Invitrogen, USA) and 150 μg/ml of G418. Large and healthy-looking colonies were isolated and expanded to individual plates. Cells were induced by 300 ng/ml doxycycline for expression of 2A pro and 48 hours later hygromycinresistant clones were collected and total RNA was extracted using RNX plus solution according to the manufacturer's protocol (Cinnagen, Iran). Complementary DNA synthesis reactions were performed using 1 μg of RNA and MMLV reverse transcriptase (Gibco BRL, Germany) with oligo(dT)18 priming in a 20-ml reaction as described by manufacturer. PCR was carried out using F-2ak and R-2a primers as described before and β-actin (internal control) primers as follows: forward primer; 5′-CACCACACCTTCTACAATGAGCTGCG-3′ and reverse primer; 5′-TACTCCTGCTTGCTGATCCACATCTGC-3′. The PCR amplification was performed for 35 cycles. The cycling conditions for β-actin were as follows: 94°C for 30 s, 58.5°C for 30 s, 72°C for 1 min with a final extension at 72°C for 5 min. A suitable double-stable Tet-On HeLa cell line was frozen to ensure a renewable source for future use.
Treatment of cells with 16-mer peptide and measurement of cell viability
The established double stable Tet-on HeLa cell line was maintained as monolayer in DMEM medium supplemented with 5% fetal bovine serum, 200 μg/ml hygromycin B, and 150 μg/ml of G418. At the time of experiment, transfected HeLa cells were induced by 300 ng/ml doxycycline, then treated with increasing concentrations of peptide (10-250 μg/ml), and cell viability was measured after 48 hours by the conventional MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay according to the manufacturer's protocol (RDSystem, USA). Results were reported as the percentages of cell viability, where the viability of the control group was arbitrary set as 100%.
Western blot analysis
To determine the activity of conditionally expressed viral 2A pro protein in stably transfected Tet-on HeLa cells, cell lysates was subjected to the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis. Following various treatments, cells were collected and cell lysates were prepared using the lysis buffer containing 150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (sodium dodecyl sulphate), 50 mM Tris pH 8.0. After centrifugation to remove cell debris, the lysates were prepared using sample buffer (3% SDS, 5% β-mercaptoethanol, 10% glycerol, 0.04% bromophenol blue, 60 mM Tris-HCl, pH 6.8), and then loaded onto a 15% PAGE in a buffer containing 0.1% sodium dodecyl sulfate. The proteins were transferred to a nitrocellulose transfer membrane (Millipore, USA), and then were probed with specific antibodies (Cell Signaling, USA). β-Actin protein was detected as a control housekeeping protein to ensure equal protein loading in all experiments. Protein bands were detected by chemiluminescence using enhanced electrochemiluminescence (ECL) reagent (Amersham Bioscience, USA) and autoradiography. Data analysis was done by Labwork data analysis (Cambridge, UK).
Computational analyses
Sequence alignment was performed using the Psi-Blast sequence alignment (Altschul et al., 1997) . Protein tertiary structure predictions were performed with the protein homology modeling Swiss modeler server using the crystal structure of HRV2 2A pro (1z8r) (Petersen et al., 1999) as a template. This program is completely automated and is capable of generating energy minimized protein models by satisfying spatial restrains on bond distance and dihedral angles extracted from the template PDB file. The input for the program modeler consisted of the aligned sequence of CVB3 and HRV2 2A pro , a steering file that gives all the necessary commands to the modeler and pdb file of the template. Many runs of modeler were carried out to obtain the most plausible model. The program was implemented using standard parameters and a database of protein with known 3D structure. To ensure the reliability of the alignment and modeling of variable surface loops, structural investigations on the graphic screen using 3D visualization program Swiss pdb viewer was performed. Docking study was performed with HEX 4.5 program (Ritchie and Kemp, 2000) . The substrate structure was estimated with molecular dynamic (MD) simulation (Kohlbacher and Lenhof, 2000; Moll et al. 2006) . A 10-ps short MD under AMBER force filed was sufficient for a short peptide and BALL output used for docking studies as ligand.
